|
1
|
Salomaa ER and Walta M: The prognosis of
lung cancer continues to be poor-treatment outcome within the
hospital district of Southwest Finland in 2004 to 2011. Duodecim.
131:69–75. 2015.(In Finnish). PubMed/NCBI
|
|
2
|
GLOBOCAN: Estimated cancer incidence,
mortality and prevalence worldwide in 2012. IARC. 2014.
|
|
3
|
Hirsh V, Major PP, Lipton A, Cook RJ,
Langer CJ, Smith MR, Brown JE and Coleman RE: Zoledronic acid and
survival in patients with metastatic bone disease from lung cancer
and elevated markers of osteoclast activity. J Thorac Oncol.
3:228–236. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mundy GR: Metastasis to bone: Causes,
consequences and therapeutic opportunities. Nat Rev Cancer.
2:584–593. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Taubenberger AV: In vitro
microenvironments to study breast cancer bone colonisation. Adv
Drug Deliv Rev. 79–80:135–144. 2014. View Article : Google Scholar
|
|
6
|
Hess KR, Varadhachary GR, Taylor SH, Wei
W, Raber MN, Lenzi R and Abbruzzese JL: Metastatic patterns in
adenocarcinoma. Cancer. 106:1624–1633. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Paget S: The distribution of secondary
growths in cancer of the breast. 1889. Cancer Metastasis Rev.
8:98–101. 1989.PubMed/NCBI
|
|
8
|
Uy HL, Mundy GR, Boyce BF, Story BM,
Dunstan CR, Yin JJ, Roodman GD and Guise TA: Tumor necrosis factor
enhances parathyroid hormone-related protein-induced hypercalcemia
and bone resorption without inhibiting bone formation in vivo.
Cancer Res. 57:3194–3199. 1997.PubMed/NCBI
|
|
9
|
Miki T, Yano S, Hanibuchi M, Kanematsu T,
Muguruma H and Sone S: Parathyroid hormone-related protein (PTHrP)
is responsible for production of bone metastasis, but not visceral
metastasis, by human small cell lung cancer SBC-5 cells in natural
killer cell-depleted SCID mice. Int J Cancer. 108:511–515. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cai Z, Chen Q, Chen J, Lu Y, Xiao G, Wu Z,
Zhou Q and Zhang J: Monocyte chemotactic protein 1 promotes lung
cancer-induced bone resorptive lesions in vivo. Neoplasia.
11:228–236. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Han JH, Choi SJ, Kurihara N, Koide M, Oba
Y and Roodman GD: Macrophage inflammatory protein-1alpha is an
osteoclastogenic factor in myeloma that is independent of receptor
activator of nuclear factor kappaB ligand. Blood. 97:3349–3353.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bogenrieder T and Herlyn M: Axis of evil:
Molecular mechanisms of cancer metastasis. Oncogene. 22:6524–6536.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer and cancer stem cells. Nature.
414:105–111. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vescovi AL, Galli R and Reynolds BA: Brain
tumour stem cells. Nat Rev Cancer. 6:425–436. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Driessens G, Beck B, Caauwe A, Simons BD
and Blanpain C: Defining the mode of tumour growth by clonal
analysis. Nature. 488:527–530. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ricci-Vitiani L, Lombardi DG, Pilozzi E,
Biffoni M, Todaro M, Peschle C and De Maria R: Identification and
expansion of human colon-cancer-initiating cells. Nature.
445:111–115. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Todaro M, Perez Alea M, Scopelliti A,
Medema JP and Stassi G: IL-4 mediated drug resistance in colon
cancer stem cells. Cell Cycle. 7:309–313. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hermann PC, Huber SL, Herrler T, Aicher A,
Ellwart JW, Guba M, Bruns CJ and Heeschen C: Distinct populations
of cancer stem cells determine tumor growth and metastatic activity
in human pancreatic cancer. Cell Stem Cell. 1:313–323. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Collins AT and Maitland NJ: Prostate
cancer stem cells. Eur J Cancer. 42:1213–1218. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
International Stem Cell Initiative.
Adewumi O, Aflatoonian B, Ahrlund-Richter L, Amit M, Andrews PW,
Beighton G, Bello PA, Benvenisty N, Berry LS, et al:
Characterization of human embryonic stem cell lines by the
international stem cell initiative. Nat Biotechnol. 25:803–816.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Miki J, Furusato B, Li H, Gu Y, Takahashi
H, Egawa S, Sesterhenn IA, McLeod DG, Srivastava S and Rhim JS:
Identification of putative stem cell markers, CD133 and CXCR4, in
hTERT-immortalized primary nonmalignant and malignant tumor-derived
human prostate epithelial cell lines and in prostate cancer
specimens. Cancer Res. 67:3153–3161. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Singh SK, Hawkins C, Clarke ID, Squire JA,
Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB:
Identification of human brain tumour initiating cells. Nature.
432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Eramo A, Lotti F, Sette G, Pilozzi E,
Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C and De
Maria R: Identification and expansion of the tumorigenic lung
cancer stem cell population. Cell Death Differ. 15:504–514. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dean M, Fojo T and Bates S: Tumour stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong
C, Huang Y, Hu X, Su F, Lieberman J and Song E: let-7 regulates
self renewal and tumorigenicity of breast cancer cells. Cell.
131:1109–1123. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Levina V, Marrangoni AM, DeMarco R,
Gorelik E and Lokshin AE: Drug-selected human lung cancer stem
cells: Cytokine network, tumorigenic and metastatic properties.
PLoS One. 3:e30772008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang J and Weinberg RA:
Epithelial-mesenchymal transition: At the crossroads of development
and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Morel AP, Lièvre M, Thomas C, Hinkal G,
Ansieau S and Puisieux A: Generation of breast cancer stem cells
through epithelial-mesenchymal transition. PLoS One. 3:e28882008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chaffer CL and Weinberg RA: A perspective
on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Christiansen JJ and Rajasekaran AK:
Reassessing epithelial to mesenchymal transition as a prerequisite
for carcinoma invasion and metastasis. Cancer Res. 66:8319–8326.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lacroix M: Significance, detection and
markers of disseminated breast cancer cells. Endocr Relat Cancer.
13:1033–1067. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pantel K, Brakenhoff RH and Brandt B:
Detection, clinical relevance and specific biological properties of
disseminating tumour cells. Nat Rev Cancer. 8:329–340. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mego M, Mani SA and Cristofanilli M:
Molecular mechanisms of metastasis in breast cancer-clinical
applications. Nat Rev Clin Oncol. 7:693–701. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hou JM, Krebs M, Ward T, Sloane R, Priest
L, Hughes A, Clack G, Ranson M, Blackhall F and Dive C: Circulating
tumor cells as a window on metastasis biology in lung cancer. Am J
Pathol. 178:989–996. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Perl AK, Wilgenbus P, Dahl U, Semb H and
Christofori G: A causal role for E-cadherin in the transition from
adenoma to carcinoma. Nature. 392:190–193. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yan B, Zhang W, Jiang LY, Qin WX and Wang
X: Reduced E-Cadherin expression is a prognostic biomarker of
non-small cell lung cancer: A meta-analysis based on 2395 subjects.
Int J Clin Exp Med. 7:4352–4356. 2014.PubMed/NCBI
|
|
42
|
Yang MH, Wu MZ, Chiou SH, Chen PM, Chang
SY, Liu CJ, Teng SC and Wu KJ: Direct regulation of TWIST by
HIF-1alpha promotes metastasis. Nat Cell Biol. 10:295–305. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sánchez-Tilló E, Lázaro A, Torrent R,
Cuatrecasas M, Vaquero EC, Castells A, Engel P and Postigo A: ZEB1
represses E-cadherin and induces an EMT by recruiting the SWI/SNF
chromatin remodeling protein BRG1. Oncogene. 29:3490–3500. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ko H, Jeon H, Lee D, Choi HK, Kang KS and
Choi KC: Sanguiin H6 suppresses TGF-β induction of the
epithelial-mesenchymal transition and inhibits migration and
invasion in A549 lung cancer. Bioorg Med Chem Lett. 25:5508–5513.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yang X, Li L, Huang Q, Xu W, Cai X, Zhang
J, Yan W, Song D, Liu T, Zhou W, et al: Wnt signaling through
Snail1 and Zeb1 regulates bone metastasis in lung cancer. Am J
Cancer Res. 5:748–755. 2015.PubMed/NCBI
|
|
46
|
Gilkes DM, Semenza GL and Wirtz D: Hypoxia
and the extracellular matrix: Drivers of tumour metastasis. Nat Rev
Cancer. 14:430–439. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Joyce JA: Therapeutic targeting of the
tumor microenvironment. Cancer Cell. 7:513–520. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lewis CE and Pollard JW: Distinct role of
macrophages in different tumor microenvironments. Cancer Res.
66:605–612. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Coussens LM, Fingleton B and Matrisian LM:
Matrix metalloproteinase inhibitors and cancer: Trials and
tribulations. Science. 295:2387–2392. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Hu T and Lu YR: BCYRN1, a c-MYC-activated
long non-coding RNA, regulates cell metastasis of non-small-cell
lung Cancer. Cancer Cell Int. 15:362015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Hsu CP, Shen GH and Ko JL: Matrix
metalloproteinase-13 expression is associated with bone marrow
microinvolvement and prognosis in non-small cell lung cancer. Lung
Cancer. 52:349–357. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wang H, Zhu Y, Zhao M, Wu C, Zhang P, Tang
L, Zhang H, Chen X, Yang Y and Liu G: miRNA-29c suppresses lung
cancer cell adhesion to extracellular matrix and metastasis by
targeting integrin β1 and matrix metalloproteinase2 (MMP2). PloS
One. 8:e701922013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Papetti M and Herman IM: Mechanisms of
normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol.
282:C947–C970. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Dimova I, Popivanov G and Djonov V:
Angiogenesis in cancer-general pathways and their therapeutic
implications. J BUON. 19:15–21. 2014.PubMed/NCBI
|
|
55
|
Weis SM and Cheresh DA: αV integrins in
angiogenesis and cancer. Cold Spring Harb Perspect Med.
1:a0064782011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Young R, Pailler E, Billiot F, Drusch F,
Barthelemy A, Oulhen M, Besse B, Soria JC, Farace F and Vielh P:
Circulating tumor cells in lung cancer. Acta Cytol. 56:655–660.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
O'Flaherty JD, Gray S, Richard D, Fennell
D, O'Leary JJ, Blackhall FH and O'Byrne KJ: Circulating tumour
cells, their role in metastasis and their clinical utility in lung
cancer. Lung Cancer. 76:19–25. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Parkinson DR, Dracopoli N, Petty BG,
Compton C, Cristofanilli M, Deisseroth A, Hayes DF, Kapke G, Kumar
P, Lee JSh, et al: Considerations in the development of circulating
tumor cell technology for clinical use. J Transl Med. 10:1382012.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Tanaka F, Yoneda K, Kondo N, Hashimoto M,
Takuwa T, Matsumoto S, Okumura Y, Rahman S, Tsubota N, Tsujimura T,
et al: Circulating tumor cell as a diagnostic marker in primary
lung cancer. Clin Cancer Res. 15:6980–6986. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Hou JM, Greystoke A, Lancashire L,
Cummings J, Ward T, Board R, Amir E, Hughes S, Krebs M, Hughes A,
et al: Evaluation of circulating tumor cells and serological cell
death biomarkers in small cell lung cancer patients undergoing
chemotherapy. Am J Pathol. 175:808–816. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Hofman V, Long E, Ilie M, Bonnetaud C,
Vignaud JM, Fléjou JF, Lantuejoul S, Piaton E, Mourad N, Butori C,
et al: Morphological analysis of circulating tumour cells in
patients undergoing surgery for non-small cell lung carcinoma using
the isolation by size of epithelial tumour cell (ISET) method.
Cytopathology. 23:30–38. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Nieva J, Wendel M, Luttgen MS, Marrinucci
D, Bazhenova L, Kolatkar A, Santala R, Whittenberger B, Burke J,
Torrey M, et al: High-definition imaging of circulating tumor cells
and associated cellular events in non-small cell lung cancer
patients: A longitudinal analysis. Phys Biol. 9:0160042012.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Palumbo JS, Talmage KE, Massari JV, La
Jeunesse CM, Flick MJ, Kombrinck KW, Hu Z, Barney KA and Degen JL:
Tumor cell-associated tissue factor and circulating hemostatic
factors cooperate to increase metastatic potential through natural
killer cell-dependent and-independent mechanisms. Blood.
110:133–141. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Schumacher D, Strilic B, Sivaraj KK,
Wettschureck N and Offermanns S: Platelet-derived nucleotides
promote tumor-cell transendothelial migration and metastasis via
P2Y 2 receptor. Cancer Cell. 24:130–137. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Hou JM, Krebs M, Ward T, Sloane R, Priest
L, Hughes A, Clack G, Ranson M, Blackhall F and Dive C: Circulating
tumor cells as a window on metastasis biology in lung cancer. Am J
Pathol. 178:989–996. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Stone JP and Wagner DD: P-selectin
mediates adhesion of platelets to neuroblastoma and small cell lung
cancer. J Clin Invest. 92:804–813. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Coleman RE: Skeletal complications of
malignancy. Cancer. 80(Suppl 8): S1588–S1594. 1997. View Article : Google Scholar
|
|
68
|
Hart IR and Fidler IJ: Role of organ
selectivity in the determination of metastatic patterns of B16
melanoma. Cancer Res. 40:2281–2287. 1980.PubMed/NCBI
|
|
69
|
Stetler-Stevenson WG and Kleiner DEJ:
Molecular biology of cancer: Invasion and metastases. Cancer:
Principles and Practice of Oncology. 6:123–136. 2001.
|
|
70
|
Müller A, Homey B, Soto H, Ge N, Catron D,
Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al:
Involvement of chemokine receptors in breast cancer metastasis.
Nature. 410:50–56. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Richert MM, Vaidya KS, Mills CN, Wong D,
Korz W, Hurst DR and Welch DR: Inhibition of CXCR4 by CTCE-9908
inhibits breast cancer metastasis to lung and bone. Oncol Rep.
21:761–767. 2009.PubMed/NCBI
|
|
72
|
Smith MC, Luker KE, Garbow JR, Prior JL,
Jackson E, Piwnica-Worms D and Luker GD: CXCR4 regulates growth of
both primary and metastatic breast cancer. Cancer Res.
64:8604–8612. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Phillips RJ, Burdick MD, Lutz M, Belperio
JA, Keane MP and Strieter RM: The stromal derived
factor-1/CXCL12-CXC chemokine receptor 4 biological axis in
non-small cell lung cancer metastases. Am J Respir Crit Care Med.
167:1676–1686. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Hirbe AC, Rubin J, Uluçkan O, Morgan EA,
Eagleton MC, Prior JL, Piwnica-Worms D and Weilbaecher KN:
Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in
bone. Proc Natl Acad Sci USA. 104:14062–14067. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Hirbe AC, Morgan EA and Weilbaecher KN:
The CXCR4/SDF-1 chemokine axis: A potential therapeutic target for
bone metastases? Curr Pharm Des. 16:1284–1290. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Nakamura ES, Koizumi K, Kobayashi M,
Saitoh Y, Arita Y, Nakayama T, Sakurai H, Yoshie O and Saiki I:
RANKL-induced CCL22/macrophage-derived chemokine produced from
osteoclasts potentially promotes the bone metastasis of lung cancer
expressing its receptor CCR4. Clin Exp Metastasis. 23:9–18. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Burns JM, Summers BC, Wang Y, Melikian A,
Berahovich R, Miao Z, Penfold ME, Sunshine MJ, Littman DR, Kuo CJ,
et al: A novel chemokine receptor for SDF-1 and I-TAC involved in
cell survival, cell adhesion and tumor development. J Exp Med.
203:2201–2213. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Lee JH, Kim HN, Kim KO, Jin WJ, Lee S, Kim
HH, Ha H and Lee ZH: CXCL10 promotes osteolytic bone metastasis by
enhancing cancer outgrowth and osteoclastogenesis. Cancer Res.
72:3175–3186. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Li N, Zhang JP, Guo S, Min J, Liu LL, Su
HC, Feng YM and Zhang HL: Down-regulation of β3-integrin inhibits
bone metastasis of small cell lung cancer. Mol Biol Rep.
39:3029–3035. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Yin H and Deng J: Advances in lung stem
cells and lung cancer stem cells. Zhongguo Fei Ai Za Zhi.
18:633–639. 2015.(In Chinese). PubMed/NCBI
|
|
81
|
Hiraga T, Ito S and Nakamura H: Cancer
stem-like cell marker CD44 promotes bone metastases by enhancing
tumorigenicity, cell motility and hyaluronan production. Cancer
Res. 73:4112–4122. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Deng X, Tannehill-Gregg SH, Nadella MV, He
G, Levine A, Cao Y and Rosol TJ: Parathyroid hormone-related
protein and ezrin are up-regulated in human lung cancer bone
metastases. Clin Exp Metastasis. 24:107–119. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Li M, Amizuka N, Takeuchi K, Freitas PH,
Kawano Y, Hoshino M, Oda K, Nozawa-Inoue K and Maeda T:
Histochemical evidence of osteoclastic degradation of extracellular
matrix in osteolytic metastasis originating from human lung small
carcinoma (SBC-5) cells. Microsc Res Tech. 69:73–83. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Yoneda T and Hiraga T: Crosstalk between
cancer cells and bone microenvironment in bone metastasis. Biochem
Biophys Res Commun. 328:679–687. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Zhang F, Wang Y, Xu M, Dong H, Liu N, Zhou
J, Pang H, Ma N, Zhang N, Pei Y, et al: MGr1-Ag promotes invasion
and bone metastasis of small-cell lung cancer in vitro and in vivo.
Oncol Rep. 29:2283–2290. 2013.PubMed/NCBI
|
|
86
|
Alves F, Vogel W, Mossie K, Millauer B,
Höfler H and Ullrich A: Distinct structural characteristics of
discoidin I subfamily receptor tyrosine kinases and complementary
expression in human cancer. Oncogene. 10:609–618. 1995.PubMed/NCBI
|
|
87
|
Valencia K, Ormazábal C, Zandueta C,
Luis-Ravelo D, Antón I, Pajares MJ, Agorreta J, Montuenga LM,
Martínez-Canarias S, Leitinger B and Lecanda F: Inhibition of
collagen receptor discoidin domain receptor-1 (DDR1) reduces cell
survival, homing, and colonization in lung cancer bone metastasis.
Clin Cancer Res. 18:969–980. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Catena R, Luis-Ravelo D, Antón I, Zandueta
C, Salazar-Colocho P, Larzábal L, Calvo A and Lecanda F: PDGFR
signaling blockade in marrow stroma impairs lung cancer bone
metastasis. Cancer Res. 71:164–174. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Sela J: Bone remodeling in pathological
conditions. A scanning electron microscopic study. Calcif Tissue
Res. 23:229–234. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Boyde A, Maconnachie E, Reid SA, Delling G
and Mundy GR: Scanning electron microscopy in bone pathology:
Review of methods, potential and applications. Scan Electron
Microsc. 1537–1554. 1986.PubMed/NCBI
|
|
91
|
Guise TA: The vicious cycle of bone
metastases. J Musculoskelet Neuronal Interact. 2:570–572.
2002.PubMed/NCBI
|
|
92
|
Karapanagiotou EM, Terpos E, Dilana KD,
Alamara C, Gkiozos I, Polyzos A and Syrigos KN: Serum bone turnover
markers may be involved in the metastatic potential of lung cancer
patients. Med Oncol. 27:332–338. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Peng X, Guo W, Ren T, Lou Z, Lu X, Zhang
S, Lu Q and Sun Y: Differential expression of the RANKL/RANK/OPG
system is associated with bone metastasis in human non-small cell
lung cancer. PLoS One. 8:e583612013. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Feeley BT, Liu NQ, Conduah AH, Krenek L,
Roth K, Dougall WC, Huard J, Dubinett S and Lieberman JR: Mixed
metastatic lung cancer lesions in bone are inhibited by noggin
overexpression and Rank: Fc administration. J Bone Miner Res.
21:1571–1580. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Bundred NJ, Walker RA, Ratcliffe WA,
Warwick J, Morrison JM and Ratcliffe JG: Parathyroid hormone
related protein and skeletal morbidity in breast cancer. Eur J
Cancer. 28:690–692. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Burton DW, Geller J, Yang M, Jiang P,
Barken I, Hastings RH, Hoffman RM and Deftos LJ: Monitoring of
skeletal progression of prostate cancer by GFP imaging, X-ray and
serum OPG and PTHrP. Prostate. 62:275–281. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Miki T, Yano S, Hanibuchi M, Kanematsu T,
Muguruma H and Sone S: Parathyroid hormone-related protein (PTHrP)
is responsible for production of bone metastasis, but not visceral
metastasis, by human small cell lung cancer SBC-5 cells in natural
killer cell-depleted SCID mice. Int J Cancer. 108:511–515. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Muguruma H, Yano S, Kakiuchi S, Uehara H,
Kawatani M, Osada H and Sone S: Reveromycin A inhibits osteolytic
bone metastasis of small-cell lung cancer cells, SBC-5, through an
antiosteoclastic activity. Clin Cancer Res. 11:8822–8828. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Iguchi H, Tanaka S, Ozawa Y, Kashiwakuma
T, Kimura T, Hiraga T, Ozawa T and Kono T: An experimental model of
bone metastasis by human lung cancer cells: The role of parathyroid
hormone-related protein in bone metastasis. Cancer Res.
56:4040–4043. 1996.PubMed/NCBI
|
|
100
|
Lorch G, Gilmore JL, Koltz PF, Gonterman
RM, Laughner R, Lewis DA, Konger RL, Nadella KS, Toribio RE, Rosol
TJ and Foley J: Inhibition of epidermal growth factor receptor
signalling reduces hypercalcaemia induced by human lung
squamous-cell carcinoma in athymic mice. Br J Cancer. 97:183–193.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Herroon MK, Rajagurubandara E, Rudy DL,
Chalasani A, Hardaway AL and Podgorski I: Macrophage cathepsin K
promotes prostate tumor progression in bone. Oncogene.
32:1580–1593. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Lawrence T and Natoli G: Transcriptional
regulation of macrophage polarization: Enabling diversity with
identity. Nat Rev Immunol. 11:750–761. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Zhang M, He Y, Sun X, Li Q, Wang W, Zhao A
and Di W: A high M1/M2 ratio of tumor-associated macrophages is
associated with extended survival in ovarian cancer patients. J
Ovarian Res. 7:192014. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Hiraoka K, Zenmyo M, Watari K, Iguchi H,
Fotovati A, Kimura YN, Hosoi F, Shoda T, Nagata K, Osada H, et al:
Inhibition of bone and muscle metastases of lung cancer cells by a
decrease in the number of monocytes/macrophages. Cancer Sci.
99:1595–1602. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Krzeszinski JY and Wan Y: New therapeutic
targets for cancer bone metastasis. Trends Pharmacol Sci.
36:360–373. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Antón I, Molina E, Luis-Ravelo D, Zandueta
C, Valencia K, Ormazabal C, Martínez-Canarias S, Perurena N,
Pajares MJ, Agorreta J, et al: Receptor of activated protein C
promotes metastasis and correlates with clinical outcome in lung
adenocarcinoma. Am J Respir Crit Care Med. 186:96–105. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Luis-Ravelo D, Antón I, Zandueta C,
Valencia K, Ormazábal C, Martínez-Canarias S, Guruceaga E, Perurena
N, Vicent S, De Las Rivas J and Lecanda F: A gene signature of bone
metastatic colonization sensitizes for tumor-induced osteolysis and
predicts survival in lung cancer. Oncogene. 33:5090–5099. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Nguyen DX, Chiang AC, Zhang XH, Kim JY,
Kris MG, Ladanyi M, Gerald WL and Massagué J: WNT/TCF signaling
through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis.
Cell. 138:51–62. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Gong M, Ma J, Guillemette R, Zhou M, Yang
Y, Yang Y, Hock JM and Yu X: miR-335 inhibits small cell lung
cancer bone metastases via IGF-IR and RANKL pathways. Mol Cancer
Res. 12:101–110. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Valencia K, Martín-Fernández M, Zandueta
C, Ormazábal C, Martínez-Canarias S, Bandrés E, de la Piedra C and
Lecanda F: miR-326 associates with biochemical markers of bone
turnover in lung cancer bone metastasis. Bone. 52:532–539. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Ell B and Kang Y: MicroRNAs as regulators
of bone homeostasis and bone metastasis. Bonekey Rep. 3:5492014.
View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Napoli LD, Hansen HH, Muggia FM and Twigg
HL: The incidence of osseous involvement in lung cancer, with
special reference to the development of osteoblastic changes.
Radiology. 108:17–21. 1973. View Article : Google Scholar : PubMed/NCBI
|
